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The list of achievements in developing pharmaceuticals and other useful products 
originating from Nature is long, and it continues to extend. Marine bioprospecting 
alone has generated three novel drugs in the last four years. The continued success 
motivates further bioprospecting efforts in the search for utilisable products from 
natural sources.   
 
In this thesis, extracts of Arctic marine organisms were screened for bioactivity. 
Bioactive extracts were dereplicated using high-resolution mass spectrometry 
(HR-MS) in an attempt to identify the component(s) responsible for the observed 
bioactivity and later isolate them using mass guided fractionation. This approach 
led to the isolation of ianthelline, a previously reported bromotyrosine-derived 
compound from the sponge Stryphnus fortis as well as two novel, highly modified 
dipeptides, breitfussin A and B, from the hydrozoa Thuiaria breitfussi. 
 
Even though the structure of ianthelline was reported in 1986 by Litaudon et al. 
very limited bioactivity data was available. The potential of ianthelline as an 
anticancer agent was explored in paper I. Ianthelline inhibited cellular growth in 
a dose- and time dependent manner by several mechanisms, including inhibition 
of mitotic spindle formation and inhibition of protein kinase activity. In paper II, 
ianthelline was investigated for antibiofouling activity. The compound was found 
to inhibit all the major stages of the biofouling process, with the main effect being 
inhibition of marine bacterial growth and the settlement of barnacles.  
 
By dereplication, breitfussin A and B were suspected to be novel compounds, with 
proton poor molecular compositions of C16H11N3O2BrI and C16H11N3O2Br2, 
respectively. The high ratio of heavy atoms to protons, in addition to low isolation 
yields, complicated the structure elucidation of the two compounds. In the end, 
their structures could be elucidated using a combination of HR-MS analysis, 
nuclear magnetic resonance (NMR) spectroscopy, computer-assisted structure 
elucidation (CASE)- and density functional theory (DFT) calculations as well as 
atomic force microscopy (AFM) imaging. This represents the first example of AFM 
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1.1 Bioprospecting  
 
Bioprospecting (or biodiversity prospecting) is the systematic search for- and 
utilisation of applicable products in Nature with the purpose of developing 
commercial products.1,2 The products found through bioprospecting can be 
categorised in the following way: chemicals (e.g. for drug development, 
agrochemicals and cosmetics), genes (recombinant pharmaceutical proteins, 
enzymes and agricultural biotechnology) and designs (e.g. architecture and 
mechanical engineering).1 In contrast to the direct value obtained from harvesting 
and consuming natural resources, such as timber harvesting, mining and oil 
extraction, bioprospecting is a value-added approach, where the natural product 
often holds little value in itself, it is their properties which makes them 
economically interesting.3,4 When bioprospecting is conducted as basic- rather 
than applied research, it is popularly termed biodiscovery. The border between 
bioprospecting and biodiscovery is not a clean cut, as biodiscovery may lead to the 
commercialisation of products and bioprospecting efforts often simply result in 
expanded knowledge about natural diversity.5 Amongst the three main habitats 
(terrestrial, freshwater, and marine), terrestrial plants have been by far most 
extensively examined for commercially interesting chemistry.1,6 This is mainly 
due to the fact that terrestrial resources traditionally have been far more easily 
accessed compared with aqueous organisms.  
 
1.1.1 The marine environment 
The ocean covers 71% of the earth’s surface and constitute more than 90% of the 
habitable space on our planet.7 It holds an estimated 50 – 80% of all life on earth 
under its surface and is home to 32 out of 33 known animal phyla, where 15 are 
exclusively marine.8,9 The habitats found in the oceans all have one thing in 
common: the presence of seawater. Apart from this, the living conditions for 
marine species can vary greatly, both between ecosystems and within a single 
ecosystem,7 Among the variable factors are temperature, light- and nutrient 
2 
 
availability, salinity, dissolved gasses, acidity, turbulence and pressure.7,10,11 In 
addition to this, most marine organisms live in complex ecosystems, where 
species diversity is high. Within these densely populated areas, also known as 
biodiversity “hot spots”, competition for nutrition and space is high, and the 
threats of being overgrown by biofouling organisms, or attacked by predators and 
pathogens, are constant.12 Many organisms, including marine sponges and corals, 
found within these ecosystems are sessile or slow moving and cannot escape 
when they are attacked by predators. Nor can they rely on a complex immune 
system when challenged by bacteria, fungi or viruses. Not surprisingly, these 
variable and challenging conditions have facilitated the evolution of rich 
biodiversity, with species employing diverse survival strategies, including an 
arsenal of highly potent chemicals to defend themselves against external threats. 
 
The oldest written record of the utilisation of natural products for their medicinal 
properties is the Egyptian Ebers Papyrus, which dates back to 2900 BC.13 This 
papyrus documents the effect of over 700 plant-based drugs.14 Historically, 
terrestrial plants was the main source of bioactive compounds used for medical 
purposes, as the sessile species living below the littoral zone at large were 
unavailable and therefore left unexplored. Following technological advantages in 
the last few decades, including self-contained underwater breathing apparatus 
(SCUBA) diving and remotely operated deep sea vessels, the oceans could be 
accessed to a much wider extent than previously, making sampling of the 
previously inaccessible organisms possible.13  
 
1.1.2 Natural products: Primary- and secondary metabolites 
All organisms need to biosynthesise a large quantity of organic compounds into 
functional end products in order to live, grow and reproduce.15 Natural products 




Some natural products represent the fundamental units of all living matter and 
are found (with variations) in all living organisms. These include common 
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carbohydrates, proteins, fats, and nucleic acids. Because of their indispensability 
and their extensive distribution, they are termed primary metabolites.17 
 
Secondary metabolites 
Other products are not biosynthesised by general metabolic pathways and have a 
more restricted taxonomic distribution, often limited to a specific species or 
genus.18 Marked differences in expression can even be found within a single 
species experiencing different environmental stress.19,20 The chemical structures 
of some selected secondary metabolites used as drugs, can be seen in figure 1. 
 
 
Figure 1 | Chemical structures of selected secondary metabolites used as pharmaceuticals. 
Lovastatin was originally isolated from the fungus Aspergillus terreus.21 It lowers serum 
cholesterol levels by competitive inhibition of 3-hydroxy-3-methylgutaryl-Coenzyme A 
reductase,22 a key enzyme in the cholesterol production pathway.23 Cyclosporine, initially isolated 
from the fungus Tolypocladium inflatum, is used as an immunosuppressant.24 Benzylpenicillin is 
an antibiotic agent, and was the first penicillin isolated from the fungus Penicillium chrysogenum 
(previously known as Penicillium notatum) by Sir Alexander Fleming in 1928.25 
 
The natural function of secondary metabolites commonly do not affect the 
immediate survival of the producing organism, and they are not essential for 
growth, respiration, storage and reproduction. They rather influence long-term 
survival by affecting the organism’s interactions with its surrounding 
environment. Because of this, they are termed secondary metabolites.  
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1.1.3 Secondary metabolites: Natural functions 
While the primary metabolites have essential structural or metabolic functions 
that are at large evident, the function of secondary metabolites are not always 
obvious. In fact, it was previously widely perceived that they were biologically 
insignificant and served no particular function.26 This perception is no longer 
valid, and secondary metabolites are now recognised as an important contributor 
for an organism’s interaction with and response to its surroundings.27 In the vast 
majority of cases, the functions of each compound and their benefits to the 
organism are not precisely understood, but their molecular modes of action are 
being increasingly elucidated28. The natural activities include protecting the 
organism against biofoulers29,30, pathogens such as bacteria, fungi and viruses,31 
predators,32,33 and against abiotic stress (Ultra violet (UV)-protectors, heavy 
metals, drought),34 to increase virulence,35 as well as improving competitiveness 
for space,36,37 or increasing the chances to reproduce.38  
 
1.1.4 Secondary metabolites: Biosynthesis 
Biosynthesis of secondary metabolites is initiated by a variety of environmental 
triggers. As many of these external factors are constantly changing, so is the 
expression of secondary metabolites under specific seasons, stress, nutrient 
availability, and developmental stages of the organism.39 The triggering factors 
are commonly referred to as elicitors and can be of abiotic-  (e.g. high or low 
temperatures, pressure, light availability, drought, salinity and UV-stress)34 or 
biotic (fungi, yeast, bacteria, predation)40 origin. In general, the biotic triggers are 
chemicals or biofactors interacting with plasma- or endomembrane receptors. 
Elicitor signal transduction leads to biosynthesis- or activation of transcription 
factors. These in turn regulate the expression of genes coding for the metabolic 
pathway enzymes needed for secondary metabolite biosynthesis.41,42 The building 
blocks used for the biosynthesis of secondary metabolite are derived from the 
primary metabolism. Despite the vast chemical diversity of secondary 
metabolites, most are derived from intermediates of, or end products from, only 
four important primary metabolic pathways.17 An overview of the pathways can 
be seen in table 1. The chemical structures of key pathway intermediates are 
shown in figure 2. 
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Table 1 | Overview of four primary metabolic pathways important for provision of 




End product examples Species 




Shikimate43 Shikimic acid 




Mevalonate45 Mevalonic acid 
DMAPP and IPP, which 
forms the basis for 













Figure 2 | Chemical structures of key building blocks acetyl CoA, shikimic acid, mevalonic 
acid and methylerythritol phosphate. 
 
The acetate pathway has a coenzyme linked key intermediate, acetyl coenzyme A 
(CoA), from which the acetyl group can be conveyed into primary- or secondary 
metabolic pathways. The mevalonate and the methylerythritol phosphate (also 
known as the deoxyxylulose 5-phosphate pathway and the non-mevalonate 
pathway48), both lead to the production of dimethylallyl diphosphate (DMAPP) 
and isopentenyl diphosphate (IPP), by way of different key intermediates. 
Secondary metabolites may also be derived from a combination of products 
originating from different primary metabolic pathways or products resulting from 
modification of these. The backbones of the secondary metabolites are formed by 
condensation of the smaller building blocks. The resulting molecular framework 
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is subsequently modified by numerous enzyme-catalysed reactions, such as 
cyclisation, elimination, rearrangement, reduction, oxidation, methylation, and 
halogenation.49  
 
This final modification of the chemical scaffolds contributes to the high degree of 
chemical diversity among the secondary metabolites. As opposed to primary 
metabolic pathways, which generally produce one (or a selected few) end 
product(s), secondary metabolic pathways often produce several.50 This 
production of many similar end products is believed to be a strategy for increasing 
the chemical diversity and thereby increasing the chances of protein interaction.51 
For example, the biosynthesis of the gibberellins leads to the production of 136 
closely related compounds, exemplified in figure 3.52 
 
 
Figure 3 | Chemical structures selected gibberellins.53 Gibberellin 3 and 7 have a four ring 
chemical scaffold and gibberellin 12, 15 and 25 display a simpler three ring chemical scaffold.  
 
In addition, bacteria and fungi use large multifunctional enzymes, termed 
nonribosomal peptide synthetases (NRPSs) and polyketide synthases (PKSs) in 
their biosynthesis of secondary metabolites. NRPSs produces nonribosomal 
peptides with broad biological activity. Many medically relevant secondary 
metabolites are produced by NRPSs, including β-lactam antibiotics and 
cyclosporine 54 (figure 1) and the lipopeptide antibiotic daptomycin55 (figure 4). 
PKS produced secondary metabolites have also resulted in several marketed 
pharmaceuticals, including lovastatin (figure 1). In addition, some secondary 
metabolites are produced by a combination of NRPS and PKS activities56 including 




Figure 4 | Chemical structures of secondary metabolites daptomycin and bleomycin. 
Daptomycin is biosynthesised in Streptomyces roseosporus by a NRPS.55 Bleomycin is 
biosynthesised in Streptomyces verticillus by a combination of a NRPS and PKS.59   
 
1.1.5 Secondary metabolites: Chemical properties 
Secondary metabolites have historically been an important source of compounds 
with properties useful to humans, and the applications for which they are utilised 
go far beyond the activities they are produced to exert.60 The beneficial properties 
include use as food, fragrances, pigments, insecticides, cosmeceuticals, 
nutraceuticals and pharmaceuticals.61-63 The chemodiversity found in Nature has 
played an essential role within the field of drug discovery and development.64 In 
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fact, approximately 60% of the pharmaceuticals marketed today are natural 
product-based drugs.65,66 
  
When compared to synthetic screening libraries, natural products are known to 
possess several chemical properties favouring them as lead structures for drug 
development.67 This is evident even when comparing secondary metabolites to 
huge sample sets of compounds produced by combinatorial syntheses 
(combinatorial compounds), produced with the purpose of generating synthetic 
compound libraries with high chemical diversity.68 Natural products in general 
have higher molecular weight (Mw), a higher number of chiral centres, ring 
structures, heavy atoms, hydrogen-bond donors and – acceptors, lower number of 
rotatable bonds, and are less lipophilic and more unsaturated.67,69,70 Taken 
together, these differences make natural products more structurally diverse, -
complex, and rigid than combinatorial compounds. It is proven that a higher 
number of chiral centres, decreased molecular flexibility and increased molecular 
size generally results in compounds with increased receptor specificity and 
potency.67 
 
The Lipinski “rule-of-five” (RO5) was generated through analysis of orally active 
drug candidates that reached phase II clinical trials, and highlights possible 
bioavailability problems if more than one rule is broken.71 The RO5 states that a 
compound is less drug-like, if it displays properties that violates more than one of 
the following physicochemical parameters: 
 Less than five hydrogen bond donors 
 Less than ten hydrogen bond acceptors 
 Mw less than 500 Daltons (Da) 
 A octanol-water partition coefficient (logP) of less than five 
 
When examining 126 14072 and 328767 secondary metabolites for Lipinski 
properties, it was found that about 80% of all displayed less than two violations 
of the RO5. Even so, it was also highlighted by Lipinski that most of the orally 
available drugs that violated more than one Lipinski rule belonged to the four 
therapeutic classes: antibiotics, antifungals, vitamins and cardiac glycosides. All 
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these classes are dominated by secondary metabolites. Lipinski suggested that the 
compounds in these classes display structural features allowing them to act as 
substrates for naturally occurring transporters.71 It is believed that secondary 
metabolites are more subjected to active transportation than synthetic products, 
as biosynthetic pathways have universal features. An exogenous natural product 
would therefore be more similar to an endogenous ligand than a foreign synthetic 
compound, and thus have a higher probability of being absorbed actively by 
transporter protein found in for example the gut wall.73 Figure 5 shows the 
molecular structure of two secondary metabolites used as drugs, where both 
violates two Lipinski rules, and one is orally available.  
 
 
Figure 5 | The chemical structures of secondary metabolite drugs paclitaxel and 
erythromycin A, both of which violate two Lipinski rules. Paclitaxel is a mitotic inhibitor used 
in cancer chemotherapy.74 With a Mw of 853 Da, a LogP of 4.49, four hydrogen bond donors and 
15 hydrogen bond acceptors, it violates two of the Lipinski rules. Paclitaxel is not orally 
bioavailable, as it cannot passively diffuse across lipid membranes, as well as being substrate to 
efflux transporters like the P-glycoprotein.75 The macrolide class antibiotic erythromycin A also 
violates two of the Lipinski rules (Mw = 733.5 Da, hydrogen bond acceptors = 14), nevertheless, it 
has an oral bioavailability varying from 20 – 40%.76  Erythromycin A is actively transported across 
lipid membranes by at least two transporters belonging to the oligopeptide transporter family.77 
 
Carrier-mediated cellular uptake of pharmaceuticals is now believed to be more 
common than previously presumed.77 It has been suggested that the RO5 cannot 
be used when determining the drug-likeness of secondary metabolites as the rules 
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are based upon passive absorption through lipid membranes, and are thus no 
longer applicable for drugs that are actively transported across membranes.78  
 
1.1.6 Marine secondary metabolites as pharmaceuticals  
In the past decades, marine life forms have been the origin of a remarkable 
number of novel secondary metabolites. In fact, since the 1960s, more than 20.000 
marine secondary metabolites have been characterised.79 They have been isolated 
from macroorganisms like sponges, corals and other invertebrates, as well as from 
algae and microorganisms.79 However, it is now becoming increasingly evident 
that the majority of compounds are actually produced by microorganisms 
associated with the collected macroorganisms.80,81 The number of isolated 
compounds from marine sources has increased steadily, from an annual number 
of approximately 20 in 1984 (the total number of all novel natural products 
reported in 1985 was 350039) to an annual number of more than 1000 in 2010.82 
As opposed to the terrestrial environment, where plants are considerably richer 
in secondary metabolites, marine invertebrates and bacteria have yielded 
substantially more bioactive natural products than marine plants.83   
 
The total number of approved drugs from the marine environment is steadily 
increasing, from four in 201084 to seven in 2014.85 The first U.S. Food and Drug 
Administration (FDA) approved marine derived drug reached the marked in 1969. 
This was the anticancer pyrimidine analogue cytarabine (Cytosar-U®), isolated 
from the Caribbean sponge Cryptotheca crypta, which acts by interfering with DNA 
synthesis.63 Since then, six more marine natural products have been approved as 
drugs (one of which is only registered in the European Union), including the 
analgesic cone snail derived peptide ziconotide (Prialt®), and the anticancer 
sponge derived macrolide eribulin mesylate (Halaven®), and four more with 
anticancer, antiviral and antihypertriglyceridemia activities.85 The chemical 
structure, generic name, and pharmaceutical applications of the marketed marine 





Figure 6A | The marketed anticancer marine derived drugs. The chemical structures and 
modes of action of the four marketed anticancer drugs Yondelis®,86 Halaven®,87 Adcetris®88 and 
Cytosar-U®.89 In Adcetris®, the marine derived secondary metabolite is covalently attached to 
cAC10, a monoclonal antibody directed against CD30, a cell membrane protein used as a tumour 
marker.90 
 
Out of these seven approved drugs, five have chemical structures optimised by 
synthesis, and are thus said to be synthetic- (analogue produced solely by 
chemical synthesis) or semisynthetic (using the natural product or a natural 






Figure 6B | The marketed marine derived drugs with other activities than against cancer. 
Three marine derived compounds with activities other than against cancer are currently 
marketed. Lovaza® is antihyperglycemic,92 Prialt® acts against chronic neurological pain93 and 
Vira-A® is an antiviral.94 
 
Another 23 marine derived compounds are currently part of the clinical pipeline.85 
Out of these, 21 are being examined for potential use as anticancer agents. Cancer 
is an area where natural products have played a particularly important role.95-97 
The remaining two compounds, tetrodotoxin and DMXBA, are being evaluated for 
analgesic properties against chronic pain and for CNS diseases like schizophrenia 
and Alzheimer’s disease, respectively. In addition, a substantial number of 
compounds are being examined for clinical potential and are thus a part of the 
preclinical pipeline.98 Their bioactivities include antibacterial, antidiabetic, 
antifungal, antiinflammatory, antiprotozoal, antituberculosis, and antiviral, in 





1.1.7 Marine secondary metabolites as antifouling agents 
Biofouling is commonly defined as unwanted attachment and subsequent 
overgrowth of submerged man-made surfaces.99,100 The biomass of the settled 
organisms causes substantial economic losses for a wide range of economic 
sectors,101 including the offshore petroleum industry, shipping, fishing and for 
other installations found in water, for example drinking water systems and power 
plants.102 The dynamic biofouling cascade is complex and can be divided into two 
phases: microfouling and macrofouling.101 
 
Microfouling 
The microfouling process is often initiated by the attachment of dissolved organic 
matter to the submerged surface, which forms a conditioning film.103,104 This is a 
process known as molecular fouling105 or biochemical conditioning,100 and begins 
within seconds after the object is submerged. This is quickly followed by the 
attachment of fouling microorganisms, including marine bacteria, fungi, diatoms, 
protozoans and algal spores.99 These sequences of events lead to the formation of 
a biofilm on the submerged surface. 
 
Macrofouling 
Macrofouling refers to settlement of macroorganisms onto the growing layer of 
microfoulers.106 The macrofouling organisms are divided into soft- and hard 
foulers. Soft foulers are shell free, and include visible algae and invertebrates, 
while hard foulers are shelled invertebrates, like barnacles, tube worms and 
bivalves.107,108 Though the attachment and growth of all fouling organisms is 
unwanted on underwater man-made surfaces, the hard macrofoulers cause 
particular damage due to their calcium carbonate skeletal structures, which 
makes them difficult to remove. In addition, their presence on ship hulls result in 
increased friction between the ship and its surrounding water, causing increased 
drag and rising fuel expenses.  
 
Antifouling 
Antifouling is the process of preventing or interfering with the biofouling cascade, 
or the removal of an already established coat of organisms from a submerged 
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object.109 Until recently, most marine installations were protected from biofouling 
by a coat of antifouling paint, where organotin compounds, like tributyltin and 
tributyltin oxide, were the active ingredients.110 However, due to severe adverse 
effects on both target and non-target organisms (including mammals),111,112 a ban 
of their use was implemented in 2008 by the International Maritime 
Organization.113 This ban led to an urgent need for new, environmentally friendly 
antifouling agents. The ideal replacement would be an environmentally neutral 
coating with a broad spectrum of activity inhibiting the settlement of biofouling 
organisms without any side effects on the biofouling organisms, or other, non-
target organisms.114 Several ways of inhibiting biofouling in an environmentally 
friendly fashion have been proposed. These include antifouling surface 
topographies inspired by the natural antifouling surfaces of mollusk shells, fish 
and mammals,108 surfaces with self-renewing properties,115 as well as chemical 
antifouling strategies. 
 
In analogy to submerged man-made surfaces, marine organisms face a constant 
threat of being overgrown by biofouling organisms. Despite this, many marine 
organisms have a clean surface, free of settling organisms. This has motivated the 
identification and extraction of natural antifouling agents from the chemical 
defence systems from marine organisms.116 In particular, the sessile and filter 
feeding marine sponges have proven to be a rich source of secondary metabolites 
with antifouling properties.116 In figure 7, the molecular structures of some 





Figure 7 | Selected marine derived compounds with antifouling activity. The antifouling 
activities of ianthelline were investigated as part of this thesis117 and compared with the activities 
of the known antifouler barettin, as a reference for the initial microfouling process.118 Oroidin, 
isolated from sponges of the Agelasidae family, inhibits the attachment and colonisation of fouling 
bacteria119 and inhibits the settlement of Balanus amphitrite larva.120 In addition, it has served as 
a template for the creation of a 50-compound library of synthetic analogues121. 5,5’-
dibromohemibastadin-1 inhibits the settlement of Balanus improvisus.122 Synoxazolidinone C and 
pulmonarin A inhibit both adhesion and growth of several marine bacteria and microalgae.123 In 
addition, synoxazolidinone C inhibits the settlement of B. improvisus larva123.     
 
One potential target for an antifouling compound is phenoloxidase. This enzyme 
is highly involved in the initial settling of several macrofoulers, including bivalves, 
barnacles and bryozoans.124,125 It catalyses the oxidation of o-quinones from 
phenols via catechols, a vital part of the polymerisation of proteins used in the 
attachment process, resulting in formation of byssus threads, anchoring the 





1.2 The bioprospecting pipeline 
 
1.2.1 Bioassay-guided isolation exemplified by the workflow at MabCent 
The application of bioassays to follow the presence of bioactive compound(s) 
through an isolation process is called bioassay-guided isolation.127 Figure 8 
illustrates the standard workflow from crude extract to pure compound 
performed at MabCent.128 The chain of events is initiated by biological screening 
of prefractionated crude extracts in various bioassays, including cell based 
anticancer-, antibacterial- and antiinflammatory assays, as well as target based 
assays for kinase inhibition. A positive bioactivity result nominates the sample for 
dereplication by ultra-high performance liquid chromatography (UHPLC)-HR-MS 
analysis. If the sample contains a suspected novel bioactive compound, or a 
previously reported compound with a novel bioactivity, the compound will be 
isolated using mass guided preparative high performance liquid chromatography 
(prep-HPLC) fractionation. After isolation, the purity of the compound is 
examined by UHPLC-HR-MS- and/or NMR analysis. This workflow resembles 
work conducted at other bioprospecting laboratories, though several variations of 
the approach exist.68 
 
 
Figure 8 | Schematic illustration of the bioassay-guided isolation workflow at MabCent.128 
 
1.2.2 Prefractionation  
Crude extracts are complex mixtures, and are often composed of hundreds of 
different constituents. Fractionation of crude extracts prior to further 
investigation is known as prefractionation. Though not essential for the output of 
novel compounds in bioprospecting, it has been shown to increase effectiveness 
of the bioactivity screening. Prefractionation increases the chances of detecting 
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bioactivity of the actual secondary metabolite in the extracts via removal of salts, 
sugars and lipids. The increased hit rate can also be accounted for by a decreased 
risk for masking the secondary metabolite activity by other interfering 
compounds, as fractions of crude extracts have reduced complexity.129 The most 
widely employed prefractionation technique is liquid chromatography (LC), 
including high performance liquid chromatography (HPLC) or flash 
chromatography, although several other techniques may be employed, including 
liquid-liquid partitioning. Prefractionation may result in any number of fractions 
ranging from a few to several hundred.127 In LC, the dissolved sample is loaded 
onto a column where sample components are separated due to their distribution 
between a solid stationary phase with a large surface area and an applied liquid 
mobile phase. During the sample run, the elution strength of the mobile phase is 
increased, resulting in a gradual elution of the applied compounds. At MabCent, 
prefractionation of the crude extracts is carried out by flash-chromatography, 
using 1 g of the crude extract resulting in eight fractions. A polymeric HP-20SS 
absorbent media is used as stationary phase. The amount eluting in each fraction 
varies between fraction number and is dependent on the natural composition of 
the crude extracts.  The fractions are dried and redissolved to a concentration of 
40 or 80 mg/mL in dimethyl sulfoxide (DMSO), dependent on the amount of 
eluting material. 
 
1.2.3 Bioassays and high throughput screening 
A bioassay is any in vitro or in vivo system used to detect the presence of a 
biologically active constituent in a sample.  
 
The bioassays can be divided into two groups:  
 Target-based assays: These assays measure the effect of compounds on a 
single, defined target.130 The targets are typically proteins, with key roles 
in in disease pathogenesis.131 Examples of targets are G protein coupled 
receptors and kinases.132  
 Phenotypic assays: In these assays, cells, tissues or whole living organisms 
are used to detect an activity.  The aim is to discover a desired effect on the 
18 
 
selected system, independent of any defined target, and does therefore not 
require any prior knowledge to the pathophysiology of the disease.   
 
In natural product drug discovery, the bioassays are utilised at different stages of 
the drug discovery process. In the initial phase of the bioprospecting pipeline, 
bioassays are conducted in a high-throughput manner to detect bioactivity in 
crude extracts or fractions. Usually a combination of bioassays is used. It is 
estimated that the screening of five million extracts will generate 1000 hits, from 
which ten leads will be generated. Out of these, five compounds will enter clinical 
trials and in the end, one will become a marketed drug.133 The initial bioactivity 
screening is followed by a more careful examination of the bioactive crude extract 
or fraction, in which a positive result nominates the sample for dereplication. 
Finally, the bioassays can be used to elucidate the bioactivity profiles of isolated 
compounds.134 
 
High throughput screening for detection of bioactivity in crude extracts or 
fractions 
High throughput screening (HTS) is the process of assaying huge numbers of 
crude extracts or fractions against selected targets in a relatively short amount of 
time.135 In order to conduct bioactivity screening in a high throughput manner, 
validated drug targets and assays suitable for detecting the bioactivity of a 
compound or an extract need to be developed. In addition to the bioassay targets, 
the necessary equipment, like microtiter plates and laboratory automation 
techniques, are needed to make HTS executable.136 Development of the HTS 
technology started in the 1950s as a way of screening for bioactivity in samples 
originating from microorganisms.134 With the development of combinatorial 
synthesis in the beginning of 1990s, efforts towards detecting bioactive natural 
products declined. From the end of the 1980s and through the 1990s, HTS analysis 
mainly evolved around screening for bioactivity in small molecule libraries 
generated from combinatorial chemistry. This failed to increase the output of new 
pharmaceuticals though,65 and from the beginning of the 21st century, HTS of 
crude extracts or fractions have regained much of its popularity. The number of 
biological targets available for testing has increased dramatically since the 
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1950s.129 As the number of available targets increased, the possibility of testing 
“old” crude extracts, fractions or isolated compounds for new activities opened 
up.137  
 
The high throughput screening bioassays 
In the systematic attempt to identify bioactive crude extracts or fractions, selected 
biochemical and/or phenotypical targets are assayed in a HTS manner as part of 
the bioassay-guided isolation process. The bioassays constituting a HTS program 
are chosen on the basis of the research area of interest for the individual 
bioprospecting laboratories. A HTS program may consist of bioassays devoted to 
detect bioactivity within one area of interest, for example anticancer agents. For 
this purpose, cell based anticancer assays, as well as kinase- and caspase 
inhibition assays may be used. It may also consist of bioassays for detecting a 
variety of activities towards a range of diseases or interest areas. At MabCent, the 
HTS program consists of assays able to detect anticancer-, antibacterial-, 
immunostimulatory- and immunosuppressive effects.128 
 
Analysis of the origin of new FDA approved drugs between 1999 and 2008 suggest 
than phenotypic screening strategies have been more productive that target-
based approaches in drug discovery.138 It has been shown that utilisation of 
phenotypic assays early in the screening cascade generates hits of higher quality, 
as opposed to target based screening.132 This is because many other factors, in 
addition to compound-target interactions come into play when a compound is to 
be used as a drug. Examples of these are membrane permeability, unspecific 
protein binding and metabolism.135  
 
In HTS of crude extracts or fractions, the assays need to detect desired bioactivity 
properties of constituents of complex samples. The assays are designed to possess 
a high capacity and deliver rapid answers at relatively low cost. In addition, they 
should be convenient, reliable, sensitive and require little material.134 HTS is 
typically performed at a single concentration, and a positive hit is followed by 
additional testing to estimate potency and target- or phenotypic specificity. 
Additional testing also aims at eliminating false positives caused by nonspecific 
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activities of constituents of the assayed crude extracts or fractions.139 These 
nonspecific interactions are not unusual and they are often seen when one or more 
constituents are present at a high concentration. As an example, when cell lines 
are screened against samples with a high fatty acid concentration these might 
cause necrotic cell death by acting on the cell wall in a detergent like manner, thus 
giving rise to a nonspecific bioactivity.129 These sample constituents are often 
called nuisance compounds. One possible way of revealing the nonspecific 
interactions is by a titration-based approach where the desired result is a dose-
response relationship.140 At MabCent, a three to four dilution curve is created for 
each active fraction, and those producing a dose-dependent result, or are active 
down to the lowest concentration point, will be further processed.  
 
1.2.4 Dereplication 
Dereplication is the rapid identification of known compounds in bioactive crude 
extracts or fractions. The process differentiates the bioactive extracts or fractions 
containing nuisance compounds or known secondary metabolites, from those 
containing secondary metabolites with novel chemistry and/or novel 
bioactivity141 prior to compound isolation. The dereplication process aims to 
make efficient use of often limited resources, as it prevents compound reisolation 
and reidentification. The strategies used in bioactive sample dereplication are 
many, and often include species and taxonomic information, bioassay results, as 
well as analytical data obtained from various chromatographic and spectroscopic 
techniques.142,143  
 
HR-MS has become the analytical tool of choice in dereplication owing to its speed, 
dynamic signal range, sensitivity and the ability to interface with chromatographic 
separation methods.144-146 The utilisation of an HPLC/UHPLC-HR-MS system is a 
powerful dereplication approach, which have been growing in popularity ever 
since the introduction of electrospray ionisation (ESI) at the end of the 20th 
century.147 ESI facilitates the transfer of analyte molecules from an uncharged 
liquid phase species to gas phase ions, hence making the hyphenation of a mass 
spectrometer to an LC systems technically feasible.148 HR-MS acquired Mw and 
isotopic patterns can be used to calculate the elemental composition of individual 
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sample compounds. The high separation efficiency of UHPLC combined with the 
acquisition of high resolution mass data from the HR-MS permits characterisation 
of individual components of samples with complex matrixes. These properties 
makes this strategy of analysis ideal for dereplication of bioactive crude extracts 
or fractions.146 Elemental compositions, bioactivity profiles and taxonomical 
information of the samples can be used to search internal or commercial 
databases. These databases offer a way of relatively straightforward comparison 
of obtained data with the huge amounts of available compound data. Several 
databases exists to facilitate these processes, including: 
 MARINLIT (http://pubs.rsc.org/marinlit/) 
 Marine Natural Product Database (http://naturalprod.ucsd.edu/) 
 Chemspider (http://www.chemspider.com/) 
 
1.2.5 Isolation 
In natural product drug discovery, isolation is an essential step in the 
identification of new chemical entities. A purified compound allows for chemical 
characterisation, as well as confirmation and further evaluation of its bioactivity. 
149 When the desired compound is present as the major metabolite in the extract, 
isolation can be rapid. This is typically not the case though, as the target compound 
often exist in trace quantities150 in a matrix of dozens of other constituents. The 
isolation of secondary metabolites from a crude extract is generally a time 
consuming process, and is known to be one of the bottlenecks in natural product 
drug discovery.68  
 
Preparative high performance liquid chromatography 
Several chromatographic techniques can be utilised for separation and 
purification of biologically active molecules from complex matrixes.151 Amongst 
the available chromatographic techniques, Prep-HPLC has emerged as the method 
of choice for secondary metabolite isolation.149,152 HPLC is the most versatile and 
robust technique for secondary metabolite isolation and offers high resolving 
power and can be scaled up as well as automated.153 The term “preparative” refers 
to a chromatographic analysis, where the objective is to collect a valuable product 
after it is separated from the other sample constituents. 
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A wide range of prep-HPLC columns are available, including normal phase-, 
reversed phase (RP)-, size exclusion- and ion exchange columns. The surface 
modification of the columns packing material determines which retaining 
interactions will occur between the sample analytes and the stationary phase. In 
the isolation of secondary metabolites, RP columns are most frequently utilised, 
as most drug-like compounds can be purified using RP-HPLC.154 Amongst the 
available RP column packing material surface modifications, octadecyl (C18) 
bonded silica is most widely used. In addition, a wide range of other RP column 
packing material surface modifications exist, like phenylhexyl, fluorophenyl and 
dihydroxypropane.149 The isolation process is often initiated by a phase of trial 
and error, where various HPLC columns and elution gradients are tested for their 
ability to separate the desired compound from the rest of the sample matrix.  
 
Mass guided preparative high performance liquid chromatography fractionation  
Using mass spectrometry (MS) to trigger collection of the compounds eluting from 
an HPLC column, is known as mass guided fractionation. Mass guided prep-HPLC 
fractionation is a powerful tool, as it combines the high separation efficiency of the 
HPLC column with the convenience of triggering the fraction collector at the 
presence of defined masses. This allows for the collection of narrow fractions as 
well as a correction for drifts in the retention times found between the individual 
injections. At MabCent, mass guided fractionation is used to isolate secondary 
metabolites from bioactive crude extracts (Figure 9).  
 
Figure 9 | Schematic illustration of the prep-HPLC-UV-ESI-single quadrupole MS system 
used for compound isolation at MabCent.  
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Several steps of purification is commonly necessary to obtain the compound in 
sufficient purities and amounts to allow for structure elucidation and further 
bioactivity confirmation and profiling. 
 
1.2.6 Structure elucidation 
Elucidating the structure of secondary metabolites often involves the 
accumulation of data from numerous sources. A wide range of spectroscopic 
instrumentation, like UV/visible- and infrared absorption spectroscopy, NMR, and 
MS, currently form the backbone of modern structure analysis.68,129 
 
High-resolution mass spectrometry 
MS is an analytical technique that measures the mass-to-charge ratio of gas-phase 
ions. High-resolution mass analysers have the ability to separate ions with very 
similar masses.155 The combination of high resolution, high mass accuracy and 
high sensitivity makes HR-MS a powerful tool for analysing complex samples like 
crude extracts or fraction. HR-MS measures exact masses with the typical 
resolution being tenth of a millimass unit (e.g 482.9079). HR-MS analysis results 
in a mass spectrum; a plot of the relative abundance of detected ions as a function 
of the mass-to-charge ratio. From the mass spectrum, the accurate mass and 
isotopic pattern of a compound can be extracted and subsequently used to 
calculate its elemental composition.156 Some mass spectrometers can fractionate 
parent gas-phase ions into daughter ions, allowing for elemental composition 
calculations of smaller parts of the parent ion.157 This information can be pieced 
together to generate structural information regarding the intact molecule. 
Without the necessity of initial isolation, this can save both time and money. This 
type of experiment is particularly useful for providing information concerning 
secondary metabolites and for amino-acid sequencing. There are many types of 
mass analysers, all separating the ions according to their mass-to-charge ratio by 
ways of various strategies. Two different high resolution mass analysers have 
been used as part of this thesis: Time-of-Flight (ToF) and orbitrap.  
 
ToF-MS determines the mass-to-charge ratio via flight time measurements. Ions 
are accelerated by an electric field to a common kinetic energy, and travels 
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through a flight tube to the detector with velocities depending on their mass. 
Lighter ions will travel faster than the heavier ions. The ToF analyser corrects for 
small differences in initial energy and angle by a combination of linear drift paths 
and ion mirrors. From the measurement of the ion flight time, the mass of the ion 
can be calculated.155  
 
Orbitrap MS is based on the electrostatically orbital trapping of ions around a 
central, spindle shaped electrode. Ions are trapped because their electrostatic 
attraction to the inner electrode is balanced by centrifugal forces. Axial oscillation 
of ion rings are detected by their image current induced on an outer electrode, 
which is split in two symmetrically pick-up sensors connected to different 
amplifiers. The mass-to-charge ratio of different ions in the orbitrap can be 
detected from respective frequencies of oscillation after a Fourier 
transformation.144,158  
 
Nuclear magnetic resonance spectroscopy 
Spectroscopy is the study of the interaction between electromagnetic radiation 
and matter. NMR spectroscopy utilises the physical phenomenon where a 
magnetic nucleus in a fixed external magnetic field absorbs and re-emit 
measurable electromagnetic radiation. The two most commonly examined nuclei 
are 1H and 13C. A parallel alignment of the previously randomly oriented nuclei 
will occur when they are subjected to an external magnetic field. The nuclei will 
align either with it or against the magnetic field, with the latter being the 
alignment requiring least energy. The difference in energy between the two spin 
states increase with increased strength of the external magnetic field. The sample 
is now applied irradiation energy in the radio frequency (rf) range. When the 
nuclei are exposed to electromagnetic radiation with a frequency matching its 
Larmour frequency, a nucleus in the lower-energy spin state will transition to the 
higher energy spin state. When the rf is switched off, the nuclei relaxes back to the 
lower energy state by re-emitting the absorbed rf energy. This emitted energy is 
of a particular resonance frequency, dependent upon the magnetic field and the 
magnetic properties of the isotope, and produces a measurable rf signal.159 This 
signal, called the resonance frequency, creates means to recover structural 
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information about the analysed molecule. The phenomenon is known as the 
chemical shift, and is the most important characteristic of a nucleus in terms of 
NMR. The shift of an individual atom depends on its atomic properties, such as 
type of nucleus, its hybridisation state and the overall electronic environment 
surrounding the nucleus (bonds, conjugation network etc.).159 
 
The measured transmitted rf frequencies are processed into an NMR spectrum.  In 
an NMR spectrum, each atom of interest is associated with a peak characterised 
by a chemical shift, an intensity and one or more couplings associated with 
interacting nuclei. More than 1000 different NMR experiments have been 
developed to provide spectra delivering various information about the examined 
nuclei, and can be either one-dimensional (1D) or two-dimensional (2D).160 1D 
experiments are spectroscopic analysis of a single nucleus. The most commonly 
used NMR experiment is 1H-NMR, providing information about chemical shifts, 
multiplet structures, homonuclear coupling constants and integrations of all 
protons present in the sample. The 1H-NMR spectrum for breitfussin A can be seen 





Figure 10 | 1H-NMR spectra obtained for the halogenated dipeptide breitfussin A obtained 
at 298 K in deuterated DMSO as part of this thesis.161 
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When the 13C nucleus is examined using a 1D-NMR experiment, each peak in the 
resulting NMR spectrum identifies a carbon atom  in a different environment 
within the molecule. Since nuclei themselves behave like small magnets, they can 
influence each other and change the energy of nearby nuclei as they resonate. This 
phenomenon is known as spin-spin coupling, and forms the basis for 2D-NMR 
experiments.159 The most important type of interaction is scalar coupling which 
occurs between two nuclei mediated through chemical bonds, and can be seen up 
to three bonds away. The most common 2D-NMR experiments for structure 
elucidation include correlated spectroscopy (COSY), nuclear overhauser 
enhancement spectroscopy (NOESY), heteronuclear multiple quantum 
correlation (HMQC) and heteronuclear multiple bond correlation (HMBC).68 All 
the different 2D-NMR experiments are designed to ascertain a different type of 
physical information about the molecule being studied. Figure 11 shows the 
structure of ianthelline with arrows highlighting observed HMBC correlations as 
well as the obtained HMBC spectrum. 
 
 
Figure 11 | The molecular structure of ianthelline with arrows highlighting C-H correlations 
as well as the HMBC spectrum recorded as part of this thesis.162 
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Homonuclear and heteronuclear couplings and spectra can be envisaged to 
represent the fingerprint of a structure, and information contained within a 
spectrum can provide sufficient information to elucidate a chemical structure. To 
elucidate the structure of complex compound a series of different spectra and 
other forms of analytical data are generally required. 
 
Atomic force microscopy 
AFM of molecules is conducted by adsorbing the compound onto a flat surface and 
scanning the surface with a narrow probe. The interactions between the tip of the 
probe and the surface generate a measurable signal that can be transformed into 
an image of the surface investigated. AFM can be used to study surfaces at high 
resolution. To obtain images at atomic resolution, the tip can be modified with a 
carbon monoxide molecule to increase image resolution. The tip is attached to a 
cantilever, which places the tip in close proximity to- and moves it across the 
surface, where the molecule of interest is placed. When the tip is moved over the 
molecules, it senses the changes in the strength of the electronic force over the 
surface. This results in movement of the cantilever, which is detected by a laser 
beam allowing for computing of AFM images (Figure 12). 
 
Figure 12 | The basic principle behind AFM analysis. An atomic force microscope probes a 
molecule adsorbed onto a surface, using a carbon monoxide molecule at the tip for sensitivity. 
Reprint from https://newscenter.lbl.gov/2013/05/30/atom-by-atom/. 
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The tip is not only able to detect the individual atoms, but also the forces 
representing the bonds formed by the electrons shared between them. In this way, 
AFM is able to create an image of the force gradient variations above the surface. 
AFM imaging has recently been used to create images of synthetic compounds 
with known structures.163 In 2010, AFM aided for the first time in the structure 
determination of a secondary metabolite.164 The structure of cephalandole A, 
isolated from an actinobacterium, was previously reported. The reported 
structure was found to be misassigned, and AFM could subsequently be used to 
correctly assign its molecular connectivity. In 2012, AFM was for the first time 
used in the structure elucidation of novel secondary metabolites, when it aided in 
the structure elucidation of the MabCent novels breitfussin A and B.161 
 
Computer-assisted structure elucidation and density functional theory 
CASE is a technique using software to generate all possible molecular structures 
consistent with a set of spectroscopic data.165 CASE was first described in the late 
1960s,166 and has since been developed into a powerful tool meant to aid in the 
structure elucidation of compounds. The number of possible structures for a given 
molecular formula is finite, due to the number of isomers corresponding to it, but 
the number of possible structures is often too high to be of any real use. CASE uses 
algorithms to calculate possible molecular structures by using obtained 
spectroscopic data as input data. DFT is a computational quantum mechanical 
modelling method, which can be used as part of structure elucidation to 
investigate the electronic structure of molecules. DFT provides the ground state 
properties of a molecule, where the electron density plays a key role. DFT can be 
used to calculate a great variety of molecular properties, including molecular 
structures, and can thus aid in structure elucidation. The powerful combination of 
CASE and DFT with experimental data makes the elucidation of molecular 
structures easier.  
 
1.2.7 Bioactivity profile of isolated compounds 
After isolation, the bioactivity profile of the purified compound is elucidated. The 
panel of bioactivities that an isolated compound is tested against will depend on 
its originally detected bioactivity and the availability of bioassays. This might 
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include testing a compound against a wide range of targets for different disease 
areas, or include assays meant to elucidate the mode of action for the compound 
for one specific disease area.  
 
1.2.8 Commercialisation of natural products 
The challenges and milestones that needs to be addressed and cleared before a 
bioactive compound with an elucidated structure and confirmed in vitro 
bioactivity can be made commercially available, are many. This is especially true 
for secondary metabolites with prospects of becoming pharmaceuticals. Any 
further work following lead identification and isolation was beyond the scope of 




Figure 13 | The sequential steps of the drug discovery and development pipeline. Figure 
adapted from167 and168. 
 
In lead optimisation, analogues of the lead compounds are produced and tested. 
In addition to potency, effectiveness and selectivity, a compound must be 
bioavailable as well as chemically- and metabolically stabile. When the drug target 
is known, in silico modelling might be conducted to enable lead compound 
modulation in a more rational way.  
 
In preclinical studies, the safety, efficacy and potential toxicity of the secondary 
metabolite, or one or a selected few of optimised analogues of the secondary 
metabolite, is tested in animal models. Satisfactory results take the compound 
through to phase I clinical trials, where it is tested in humans for the first time, to 
evaluate its safety. The efficient concentration range and toxicity of the compound 
will determine the dosage range. In addition, side effects are identified, as well as 
pharmacokinetic properties. In phase II clinical trials, the compound is tested for 
its efficiency in treating patient with the disease or the condition targeted by the 
medication.  In the following step, phase III, blinded clinical trials are designed to 
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verify the benefit of the compound in a larger targeted patients population, 
compared to known treatments and placebo. The studies, normally conducted 
over several years, can generate the required data for marketing approval. Overall, 
the preclinical and clinical development is a time consuming and expensive 
process.  In the last phase, marketing and safety monitoring (also termed phase 
IV), clinical trials may be conducted to meet requirements set by the approving 
authorities (e.g. the FDA), to test the drug with additional patient populations, or 




























2. AIM OF THE THESIS 
 
The work included in this thesis has been performed as part of the ongoing work 
at MabCent. The overall aim was to search for novel bioactive natural products, as 
well as previously known compounds with novel bioactivities. The target 
activities are mainly pharmaceutically oriented, and include treatment of cancer, 
diabetes, inflammation and bacterial infections. In addition, related bioactivities 
such as inhibition of biofouling have been examined.  
 
The main objectives of the present study were to: 
 
 Identify bioactive crude extracts or fractions through primary bioactivity 
screening 
 Dereplicate the bioactive crude extract or fraction in order to identify the 
bioactive component(s) 
 Isolate the active metabolite(s) 
 Elucidate the structures of the active metabolite(s) 
 Confirm the initially observed bioactivity and conduct further thorough 
bioactivity elucidation 
















3. SUMMARY OF PAPERS 
 
Paper I 
Kine Ø. Hanssen, Jeanette H. Andersen, Trine Stiberg, Richard A. Engh, Johan 
Svenson, Anne-Marie Genevière, Espen Hansen.  
 
Antitumoral and Mechanistic Studies of Ianthelline Isolated from the Arctic 
Sponge Stryphnus fortis.  
 
Anticancer research, 32, 2012, 4287 – 4297.  
 
Cytotoxicity of ianthelline (Figure 14) was tested against eleven cell lines and the 
effects of ianthelline on key cell division events were studied in sea urchin 
embryos. Tyrosine kinase Abl, cAMP-dependent protein kinase A (PKA), protein-
tyrosine phosphatase 1B, and a panel of 131 kinases was further tested for 
ianthelline sensitivity. The effect of ianthelline was further found to be time 
dependent, as it inhibited the human melanoma cancer cell line A2058 in a dose- 
and time dependent manner. Disturbed mitotic spindle formation was seen in sea 
urchin embryos exposed to ianthelline. In addition, pronuclear migration and 
cytokinesis were severely inhibited. No effect on DNA synthesis was detectable. 
Ianthelline did not significantly inhibit Abl, but did show weak dose-dependent 
inhibition of PKA and PTP1B. Ianthelline strongly inhibited (to residual activity ≤ 
10%) three out of 131 tested kinases, showing a Gini coefficient of 0.22 for the 
degree of kinase inhibition selectivity. These results demonstrate that ianthelline 
is a cytotoxic marine compound and it exerts its antiproliferative effect by several 
mechanisms that includes inhibition of mitotic spindle formation and inhibition of 
protein kinase activity.  
 




Kine Ø. Hanssen, Gunnar Cervin, Rozenn Trepos, Julie Petitbois, Tor Haug, Espen 
Hansen, Jeanette H. Andersen, Henrik Pavia, Claire Hellio, Johan Svenson 
 
The Bromotyrosine Derivative ianthelline Isolated from the Arctic Marine 
Sponge Stryphnus fortis Inhibits Marine Micro- and Macrobiofouling. 
 
Marine Biotechnology, 2014, 10.1007/s10126-014-9583-y. 
 
The ability of ianthelline (Figure 14), a bromotyrosine derivative isolated from the 
Arctic marine sponge Stryphnus fortis, to inhibit marine biofouling was examined. 
Inhibition of the initial stages of the biofouling process was investigated by 
exposing ten strains of marine bacteria and eight microalgal strains to the 
compound. Both inhibition of surface adhesion and growth were investigated. The 
potential of ianthelline as an inhibitor of macrofouling was investigated by 
exposing settling cyprid larvae of B. improvises to the compound. In addition, 
ianthelline was further explored for inhibitory activity against the blue mussel 
(Mytilus edulis) phenoloxidase. Finally, ianthelline was tested for activity against 
seven terrestrial bacterial strains known to cause disease in human, and for 
antibiofilm activity against S. epidermidis.  
 
Ianthelline was found to inhibit all the major stages of the fouling process, with 
the main activity being against marine bacteria (Minimum inhibitory 
concentration (MIC) as low as 0.1 µg/mL) and the settlement of barnacles (Half 
maximal inhibitory concentration (IC50) = 3 µg/mL).  A lower activity was seen 
against microalgae and the blue mussel enzyme phenoloxidase. In addition, 
ianthelline was found to display activity against all human pathogenic bacteria 










Kine Ø. Hanssen, Bruno Schuler, Antony J. Williams, Taye B. Demissie, Espen 
Hansen, Jeanette H. Andersen, Johan Svenson, Kirill Blinov, Michal Repisky, Fabian 
Mohn, Gerhard Meyer, John-Sigurd Svendsen, Kenneth Ruud, Mikhail Elyashberg, 
Leo Gross, Marcel Jaspars, Johan Isaksson 
 
A combined Atomic Force Microscopy and Computational Approach for the 
Structural Elucidation of Breitfussin A and B: Highly Modified Halogenated 
Dipeptides from Thuiaria breitfussi. 
 
Angewandte Chemie International Edition, 51, 2012, 12238-12241. 
 
Breitfussin A and B were isolated from the Arctic, marine hydrozoan Thuiaria 
breitfussi. Their structures were solved used a novel combination of AFM, CASE, 
and DFT calculations, as well as HR-MS and NMR. Visualisation by AFM 
determined all the connection points of the cyclic systems and the other 
substituents. The elucidated structure and the AFM image of breitfussin A can be 




Figure 15 | The elucidated molecular structure of breitfussin A overlaid the AFM image of 





4. GENERAL DISCUSSION 
 
As highlighted throughout the introduction, Nature is a rich source of bioactive 
secondary metabolites with diverse chemistry. To identify secondary metabolites 
with the potential of becoming commercially available products, research needs 
to be put into the initial stages of natural compound discovery: the bioprospecting 
pipeline. In this thesis, the established bioprospecting pipeline found at MabCent 
was used to discover two novel compounds where the full bioactivity profile 
remains to be elucidated (Breitfussin A and B, Paper III), as well as a previously 
reported compound with novel bioactivities (Ianthelline, Paper I and II).  
 
4.1 Sample supply  
Bioprospecting is dependent upon the provision of biological samples, and one of 
the major hurdles, especially in marine bioprospecting, is sample availability.169 
The samples of S. fortis and T. breitfussi used in this thesis were provided by the 
Norwegian national marine biobank (Marbank). Marbank undertakes several 
annual research cruises, collecting samples from Arctic- and sub-Arctic waters in 
Norway, with the goal of collecting at least one kilogram of each species for further 
processing. The collection is regulated, and conducted according to, among others 
regulations, the Norwegian marine resource act, the Norwegian nature diversity 
act, the law of the sea convention and the convention on biological diversity. 
Pictures of the collected specimens of S. fortis and T. breitfussi can be seen in figure 
16 and an overview of collected amounts, collection site, amounts of isolated 




Figure 16 | Specimens of S. fortis and T. breitfussi. Photo: Robert Johansen, Marbank. 
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Table 2 | An overview of collection site, collected wet weight, weight of the isolated 
compound and isolation yield of ianthelline and the breitfussins, isolated from S. fortis and 
T. breitfussi. 






Off the coast of 
Spitsbergen 
2.015 kg Ianthelline: 210 mg 0.0104% 
T. breitfussi 
Off the coast of 
Bear Island 
0.309 kg 
Breitfussin A: 6.2 mg 




Understandably, the total quantity of organic material that can be collected during 
a research cruise is limited, and a balanced relationship between the quantities of 
each collected sample and the total number of collected samples exists. Ianthelline 
was isolated in amounts that allowed for structural determination and thorough 
bioactivity profiling. The low quantity of collected T. breitfussi and low isolation 
yields of breitfussin A and B, left one wishing that more of the original sample had 
been collected.  
 
Pure bioactive compounds need to be isolated in amounts allowing structure 
elucidation, bioactivity confirmation, and also preferably thorough biological 
characterisation. This task has proven to be a challenge for many bioactive marine 
derived secondary metabolites, and limited amounts of compounds available 
might severely delay, or even prevent, the development of commercial products. 
One example is the cytostatic sponge derived polyketide halichondrin B, where 1 
tonne of sponge material was processed for isolating 300 mg of a mixture of two 
halichondrin analogues.170 Another example is the ecteinascidins and their lead 
compound trabectedin (Molecular structure shown in figure 6A). Trabectedin, 
discovered in 1990 and now marketed as Yondelis®, gave a yield of 0.0001% when 
isolated from its natural source, the tunicate Ecteinascidia turbinata.171 The 
tunicate could not be harvested in quantities sufficient for providing the amount 
of trabectedin needed for preclinical trials, delaying the bioactivity profiling of the 
compound. The final solution to the supply problem was solved by a semisynthetic 
process, where trabectedin is produced from cyanosafracin B.171 
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In order to overcome supply problems, most marketed drugs are being produced 
synthetically or semisynthetically (with some important exceptions, like 
morphine, which is extracted from the poppy Papaver somniferum). The synthesis 
of natural products is not necessarily straightforward, owing to the complexity of 
the compounds. The total synthesis of halichondrin B was developed, but could 
not provide sufficient amounts to put the compound to clinical trials. Hundreds of 
analogues of the compound were later produced. One of these, eribulin mesylate, 
is now approved as a pharmaceutical under the generic name Halaven®172 (See 
figure 6A for chemical structure). The synthesis of ianthelline is already 
published,173 and more compound could be made available independently of 
availability of S. fortis. The breitfussins are novel compounds, and T. breitfussi has 
thus to be recollected to allow for reisolation or a synthetic route towards 
breitfussin A and B has to be developed to obtain higher compound quantities. 
 
4.2 Macroorganism associated microorganisms 
Marine microorganisms are a prolific source of structurally diverse bioactive 
metabolites.174 It is now becoming increasingly evident that for many of the 
isolated bioactive marine secondary metabolites, the collected macroorganism 
originally believed to be the producer of the secondary metabolite, simply was the 
host for or predator of the true producing microorganism. This is true for many of 
the marketed marine derived drugs, as well as for several of the marine derived 
compounds in the clinical pipeline. The pie charts in figure 17 illustrate the 
difference between collected organisms and suspected biosynthetic origin of 
selected marine derived secondary metabolites,91 out of which 80% are suspected 
to be produced by bacteria or cyanobacteria. 
 
This realisation came from the observation of identical marine secondary 
metabolites isolated from marine invertebrates and microorganisms with similar 
of even identical chemical structures. One example of such compounds is the 
antitumour agent dolastatin 10. It was originally isolated from the mollusc 
Dolabella auricularia, and later from the marine cyanobacterium Symploca species 
VP642.175 A synthetic analogue of dolastatin 10, monomethyl auristatin E, is now 
part of the antibody-drug conjugate marketed as Adcetris® (Molecular structure 
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shown in figure 6A).176 Another example is the protein kinase inhibitor 
staurosporine. As opposed to dolastatin 10, it was originally isolated from a 
microorganism, the bacterium Streptomyces staurosporeus,177 and later from the 
tunicate Eudistoma toealensis.178 
 
 
Figure 17 | Pie charts showing the collected source and predicted biosynthetic source of 
marine derived or inspired drugs and clinical trial agents. Pie chart A shows the collected 
source of 20 marine secondary metabolites used as pharmaceuticals or is part of the clinical 
pipeline as of January 2012. Pie chart B shows the suspected biosynthetic origin of the same 
compounds. Figure made with inspiration from reference 91. 
 
Due to this, much focus is now devoted to the study and cultivation of marine 
microorganisms. An increased focus on fermentation of microorganisms as a 
source of organic material available for crude extract production and bioactivity 
screening might also help surpass the limitation of biological material needed a 
successful product development. This can result in both a higher number of 
screenable samples while also eliminating the supply problem. For example, the 
EU-funded PharmaSea project (http://www.pharma-sea.eu/), an international 
collaboration between bioprospecting laboratories all over the world, exclusively 
works with extracts produced from fermented bacteria in the search for novel 
antibiotics, antiinflammatory and antineurodegenerative compounds.  
 
While fermentation of microorganisms undoubtable is a good strategy, one should 
not refrain from collecting macroorganisms like S. fortis and T. breitfussi for 
bioprospecting purposes. Many microorganisms are host-specific and not found 
in the surrounding seawater nor in any other habitats, and many of these 
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microorganisms have proven difficult to cultivate.179,180 Microorganisms living in 
symbiosis with macroorganisms can be responsible for a large portion of the 
biomass of their host organism. For marine sponges, microorganisms comprise up 
to 40% of sponge volume. The collected microorganism biomass may therefore 
very well be substation enough to enable secondary metabolite isolation. In 
addition, the microorganisms might only produce the desired compound under 
certain environmental or ecological conditions. The growth conditions triggering 
the production of bioactive secondary metabolites can be difficult to mimic when 
the microorganisms are fermented in the laboratories.181 
 
S. fortis is a marine sponge and T. breitfussi a marine cnidarian. Both phyla are 
known to exist in symbiosis with microorganisms. It has been indicated that the 
microbial symbionts of marine sponges are producers by enzymes involved in the 
halogenation of secondary metabolites.182 It is still not known whether ianthelline, 
or the wide range of other bromotyrosine derivative isolated from marine sponges 
are biosynthesised by bacterial symbionts, or as a collaboration between 
symbionts and host enzymes.183 The true biosynthetic origin of the breitfussins 
also remains to be confirmed.  
 
4.3 Hit rate 
As discussed in the introduction, it is estimated that screening of five million 
fractions results in 1000 hits, giving an overall hit rate of 0.02%. One goal of a 
screening library is to provide a high level of structural diversity in order to 
optimise the bioactivity screening and the identification of lead structures. This 
can be accomplished by sampling a wide variety of species, or by collecting in 
unexplored ecological niches. It is hypothesised that tapping into largely 
unexplored marine diversity has great potential for yielding active extracts at a hit 
rate much larger than previously reported. Schupp et al. reported an increased hit 
rate when samples were collected in the largely unexplored biodiversity at a depth 
of 50 – 150 m around Guam.184 The collected samples were able to generate a hit 
rate of 42% in the initial bioactivity screening.184 The authors argued that 
sampling in previously unexplored locations as well as previously unexplored 
species will lead to an increased bioactivity hit rate in initial screening. The Arctic 
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and Sub-Arctic environment is a largely unexplored habitat, and the collection of 
organisms here for bioprospecting can therefore easily be rationalised.    
 
4.4 Crude extract preparation 
Both S. fortis and T. breitfussi were subjected to extraction, resulting in an aqueous 
and an organic extract for both organisms. In the bioactivity screening performed 
as part of the Norwegian national screening platform (Marbio), the aqueous 
extracts deliver a lower hit rate than the organic extracts. The aqueous extracts 
are prepared not only to become an additional fraction for bioactivity screening. 
It also clears the organic extract of inorganic salts and other unwanted compounds 
and can concentrate the active principal component in the extract.  
 
4.5 Bioactivity detection in prefractionated crude extracts 
Both target based and phenotypic bioactivity screening assays were used to 
evaluate the bioactivity of the crude extracts of S. fortis and T. breitfussi, see table 
3. The initial bioactivity screening for antibacterial activity consists of six bacteria 
strains, where two are Gram positive and four are Gram negative. All the tested 
bacteria strains are human pathogens. In addition, the antidiabetic type II target 
protein tyrosine phosphatase 1B and the Herpes simplex virus were part of the 
initial bioactivity screening. A positive result in the initial bioactivity screening 
nominated the active fraction(s) for further bioactivity testing. 
 
Table 3 | An overview of the bioactivity assays used as part of the bioactivity guided 
fractionation of fractions prepared from S. fortis and T. breitfussi. 
Assay Type Target 
Anticancer 
Phenotypical Human melanoma cell line 
Target based Kinase inhibition: PKA and Abl 
Antibacterial Phenotypical 
E. coli, S. aureus, MRSA, P. aeruginosa, E. 
faecalis and S. epidermidis  
Biofilm Phenotypical S. epidermidis 
Immunostimulants Phenotypical TNF-α and IL-1β 
Anti-inflammatory Phenotypical TNF-α and IL-1β 
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4.6 Dereplication of bioactive organic extracts of S. fortis and T. breitfussi 
The organic extracts of S. fortis and T. breitfussi were both subjected to 
dereplication by HR-MS analysis. Based on a combination of the results from the 
initial bioactivity screening and the dereplication, isolation of ianthelline and the 
breitfussins were initiated.  
 
Stryphnus fortis 
In the extract of S. fortis, the presence of one major peak was evident, eluting at 
approximately 35% aqueous acetonitrile from a C18 column. The mass spectrum 
of the peak can be seen in figure 18 and revealed a compound with a dibrominated 
isotope pattern. The calculated protonated elemental composition was 
C15H18Br2N5O3, an elemental composition found to match ianthelline based on 
natural product database searches.  
 
 
Figure 18 | Isotope pattern of the dibrominated compound discovered in the organic extract 
of S. fortis later confirmed to be ianthelline.  
 
Thuiaria breitfussi 
HR-MS analysis of the organic extract of T. breitfussi revealed the presence of 
several compounds with halogenated isotope patterns eluting at approximately 
70% aqueous acetonitrile from a C18 column. Breitfussin A and B were found as 
two of these peaks, and had monobrominated- and dibrominated isotope patterns 
with calculated protonated elemental compositions of C16H12N3O2BrI and 
C16H12N3O2Br2, respectively (Figure 19). As can be seen from the calculated 
protonated elemental compositions, the difference is that breitfussin A has one Br 
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and one I, while Breitfussin B is halogenated with two bromine atoms. It was 
therefore hypothesised that the two compounds shared a common molecular 
framework, and that the difference between the two might be as simple as the 
presence of a bromine- or an iodine atom in the same position. When searching 
the databases, the two compounds did not match any previously described 
compounds, and were thus believed to be novels.  
 
 
Figure 19 | Isotope pattern for breitfussin A and B. Breitfussin A has the characteristic 
monobrominated isotope pattern, and breitfussin B the characteristic dibrominated isotope 
pattern. 
 
4.7 Preparation of samples for mass guided prep-HPLC isolation 
The organic extracts of S. fortis and T. breitfussi were prepared for mass guided 
prep-HPLC using liquid-liquid partitioning. The overview of the two partitioning 
strategies can be seen in figure 20.  The sample preparation of T. breitfussi was 
quite labour intensive, using a series of two-phase mixtures in separation funnels 
to sort components by partitioning coefficients. HR-MS analysis was used to 
identify the fractions containing breitfussin A and B. In hindsight, flash 
chromatography might have been a more practical choice for sample preparation. 
Flash chromatography is less labour intensive, uses less organic solvent and 
eliminates the waiting time caused by formation of emulsions between two 
phases. Preparation of organic extracts prior to compound isolation on HPLC 
brings several advantages. It aims to remove impurities, and thereby generate a 
cleaner starting point for compound isolation. By removing impurities, the 
concentration of the desired compound is increased. With this, the capacity of the 
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HPLC column can be utilised better as a higher quantity of the interesting analyte 
can be injected onto it in every injection. This results a lower number of total 
injections needed as part of the compound isolation. In addition, it spares the 




Figure 20 | The two different sample preparation liquid-liquid partitioning strategies used 
for the organic extract of S. fortis and T .breitfussi. 
 
4.8 Isolation of ianthelline and the breitfussins 
Two important factors are commonly manipulated in order to isolate secondary 
metabolites from complex crude extracts by HPLC: The stationary phase of the 
HPLC column and the eluent gradient. 
 
Selection of high performance liquid chromatography columns 
When choosing columns for the purification of the breitfussins, a small volume of 
the organic T. breitfussi extract was injected onto HPLC columns with different 
surface chemistry. For every tested HPLC column, the ability of the column to 
separate breitfussin A and B from the impurities was evaluated. Based on these 
results, both breitfussins were initially isolated using an HPLC column with a 
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fluorophenyl stationary phase. A base peak intensity chromatogram from the 
initial isolation can be seen in figure 21.  
 
 
Figure 21 | Base peak intensity chromatograms from the initial isolation of breitfussin A 
and B from the organic extract of T. breitfussi separated over a RP fluorophenyl HPLC 
column using the masses of the breitfussins as fraction triggers. Also visible in the 
chromatogram is the collection of isomers of breitfussin A and B. The collected breitfussin B peak 
was a mixture of two breitfussin isomers with equal masses, inseparable in the initial isolation 
step. They were later separated using a C18 HPLC column. 
 
A single purification step is rarely sufficient for obtaining a pure active compound 
from a crude extract. Normally, when a compound of interest is subjected to a 
second HPLC purification step, columns with stationary phases different from the 
initial HPLC column are useful. While breitfussin A was further purified using the 
same fluorophenyl HPLC column with a slightly different elution gradient, 
breitfussin B was purified in a second step using a column with C18 stationary 
phase. As a final purification step, both samples were run through a prep-HPLC 





Optimisation of an elution gradient 
To utilise the separation capacity of HPLC columns, a mobile phase gradient needs 
to be optimised for the isolation of the compounds of interest. When a RP-HPLC 
column is used, lipophilic sample constituents will interact with the hydrophobic 
surface of the stationary phase and an organic solvent is used to cause analyte 
elution. For both ianthelline and the breitfussins, elution gradients with increasing 
amounts of acetonitrile in water with 0.1% formic acid were used to separate the 
compounds of interest from the different sample components. In particular, the 
separation of breitfussin B and its closely eluting isomer required careful 
optimisation of the elution gradient.  
 
Mass- and timed-events triggering of fraction collection 
Ianthelline was found in high quantities in the organic extract of S. fortis, and was 
easily collected using a C18 column. However, one impurity could not be separated 
using different gradients. The ion chromatogram of the impurity and ianthelline 
can be seen in figure 22.   
 
 
Figure 22 | Ion chromatogram of ianthelline and the separated impurity.  
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The impurity was finally eliminated from the collected fraction of the ianthelline 
peak by delaying the collection using timed events as opposed to triggering by 
mass. The small amount of ianthelline lost at the beginning of the peak was 
considered expandable, and the isolation resulted in 47.5 mg of pure end product 
from the initial isolation round.  
 
4.9 Structure elucidation 
In natural product drug discovery, one of the major bottlenecks is structure 
elucidation. For ianthelline, a previously reported compound with published NMR 
data the structure confirmation was rapid, and could be done on the basis of HMBC 
and HSQC experiments, as well as HR-MS analysis. The structures of the novel 
breitfussins on the other hand, proved to be difficult to unambiguously elucidate 
using the readily available HR-MS and NMR experiments. Structure elucidation of 
unknown compounds using NMR relies heavily on the ability to detect interactions 
between neighbouring protons, and between protons and their neighbouring 
carbon atoms. The breitfussins are proton poor compounds, with a ratio of heavy 
atoms to protons of approximately 2:1. Because of this, structure determination 
with NMR was challenging, mostly due to a silent region in the centre of the 
compounds. Following NMR analysis, no unambiguous structure could be 
determined. On the basis of HR-MS analysis and 2D-NMR experiments, the 
fragments shown in figure 23 were determined to be the most likely substructures 
of the two compounds, although several other possible substructures could not be 













Figure 23 | A graphical representation of the NMR correlations found for breitfussin A and 
B : COSY (green), HMBC (blue) and ROESY (red) for the most likely substructures that could 
be puzzled together based on HR-MS and NMR analysis. 
 
The structures elucidation of the breitfussins had come to a complete halt before 
the opportunity of AFM imaging appeared. The breitfussins are planar 
compounds, and breitfussin A proved to be an excellent candidate for AFM 
imaging. The obtained AFM image of breitfussin A with highlighting of key 
observations can be seen in figure 24. The image revealed a bicyclic system that 
included a five-membered ring (the indole). In addition, it showed two connected 
rings and the connective point between the rings. The halogenations were visible 
as elongated spots, and a bulky methoxy group could also be seen. One part of the 
AFM image could not readily be explained by the structure of breitfussin A (circled 
in figure 24). This part of the image is believed to be an experimental artifact. It is 
believed to be a salt, an impurity from the solvent or an iodine atom that has 
disassociated from one molecule and that is now attached to this particular 
molecule. However, no absolute explanation for this observation is available. The 
AFM image excluded all tricyclic structural options and allowed for the focus of 
structural determination of the middle part of the breitfussins. CASE and DFT 
calculations of breitfussin A were conducted, both resulting in the structure now 




Figure 24 | AFM image of breitfussin A with key observation highlighted.  
 
The combination of AFM imaging with the more traditional structure elucidation 
methods HR-MS, NMR and to a certain extent CASE and DFT, made the structure 
elucidation of breitfussin A and B possible. This represents a novel combination of 
structural elucidation techniques, and resulted in the opportunity to further 
investigate the bioactivity of the breitfussins as well as to potentially produce 
analogues of the compounds if desired.  
 
4.10 Bioactivity profiling of ianthelline 
The bioactivity of ianthelline was examined in paper I and II. The activities 
explored in the bioactivity profiling were detected in initial anticancer- and 
antibacterial screening assays of the crude organic extract of S. fortis. The results 
were followed up with phenotypic assays for further exploration of the bioactivity 
of ianthelline after isolation. Later, the mode of action of ianthelline was evaluated 
by using target based assays. 
 
In paper I, the anticancer potential of ianthelline was explored. After isolation, the 
effect of ianthelline was elucidated by exposing one non-malignant and ten 
malignant cell lines to ranging compound concentrations. The result showed that 
ianthelline had a modest, dose-dependent activity against seven cell lines 
(including the non-malignant cell line). Furthermore, initial mode of action studies 
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revealed that the effect was time dependent, increasing with increasing exposure 
time. The combined results from the initial phenotypic bioassays indicated that 
ianthelline might interfere with a cellular process not common for all the exposed 
cell lines, and also that it affected an ongoing cellular process rather than causing 
rupture of the cell membrane, leading to death by necrosis.  
 
These observations motivated the elucidation of the mode of action behind the 
observed bioactivity. Ianthelline was tested against a panel of 131 kinases at the 
international centre for kinase profiling in Dundee, as well as in two in-house 
kinase inhibition assays (kinases: Protein kinase A and Abl). Calculation of the Gini 
coefficient based on the results, showed that ianthelline inhibited the kinase panel 
with a modest selectivity. Despite the low selectivity, differences in kinase 
inhibition were observed. Three kinases were significantly inhibited: 
transforming growth factor beta activated kinase 1 (TAK1), serum and 
glucocorticoid-induced kinase 1 (SGK1) and protein kinase Bβ (PKBβ). All three 
kinases are commonly overexpressed or constitutively active in human cancers, 
including colon and breast cancer.185-187 Another interesting observation was the 
apparent selectivity in the inhibition seen between the closely related kinases 
PKBβ and protein kinase Bα (PKBα). 
 
Furthermore, fertilised sea urchin P. lividus eggs were used as test organism for 
examining the effect of ianthelline on cell cycle progression. Inhibition of cell 
division was found to be dose dependent. Against the same test organism, the 
effect of ianthelline on DNA synthesis, microtubule organisation and cytokinesis 
were also explored. No visible inhibition of DNA replication could be detected. 
Ianthelline was found to severely inhibit mitotic spindle formation, and thus also 
cytokinesis. Disruption of the highly dynamic mitotic-spindle microtubules is 
among the most successful targets for anticancer therapy, and is the cellular 
process targeted by paclitaxel.188 The concentration of ianthelline, at which the 
mitotic-spindle dynamics are disturbed, is higher than the common low micro- to 
nanomolar bioactive concentrations of marketed anticancer drugs. However, 
ianthelline may be used as a scaffold production of analogues with structures 
optimised for microtubule and/or protein kinase interactions.  
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In paper II, the potential of ianthelline as an antibacterial drug, as well as an 
antifouling compound was elucidated. This was motivated by the initial 
antibacterial bioactivity screening results, as well as database searches revealing 
that compounds with chemical structures similar to ianthelline exerted 
antifouling activities.  
 
The MIC of ianthelline was determined against seven human pathogenic bacteria.  
The ability to inhibit the biofilm formation of S. epidermidis was also studied. The 
lowest MIC value was found against Gram-positive S. aureus. Furthermore, the 
effect of ianthelline against the growth and adhesion of ten marine bacteria and 
eight microfouling microalgae was explored, to elucidate the potential of 
ianthelline as an inhibitor of microfouling. The growth of two strains of marine 
bacteria and one microalgal strain revealed MIC values as low as 0.1 µg/mL. Three 
bacteria strains and two microalgae strains had MIC values of 1 µg/mL. Growth of 
marine bacteria and microalgae was generally inhibited at lower concentrations 
than their adhesion, except for at the bacteria strain Vibrio natriegens, where 
adhesion was inhibited at a lower concentration. The potential of ianthelline as an 
antifouling agent was further explored by testing its ability to inhibit the 
settlement of B. improvisus. 
 
Both antibacterial pharmaceuticals and antifouling agents should ideally exert no 
side-effects to human or any other exposed organism. When it comes to biofouling 
organisms, this is also true for the fouling organism which should ideally only have 
its attachment inhibited, and should not experience any other effects. The 
potential of ianthelline as an antifouling agent thus becomes even more evident 
when the results of paper I and II are compared. The active concentration range 
for the antifouling activities of ianthelline is substantially lower than active 
concentration range against the tested cell lines. A similar gap between active 
concentrations is also evident when comparing the activity against cell cycle 
progression of the sea urchin P. lividus (IC50 value = 53 µM), while the settlement 
of B. improvisus cyprid was inhibited at significantly lower concentrations (IC50 
value of 3 µg/mL, corresponding to 6.3 µM). The gap between the active 
antifouling concentration and the concentrations at which ianthelline causes 
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damage to surrounding marine species thus appears to be significant. Further 
analysis needs to be conducted though, to elucidate the potential toxic effects of 
ianthelline to non-target organisms.  
 
4.11 Further work 
During this project, the bioactivity profile of the previously reported compound 
ianthelline was elucidated. Based on these results it would be interesting to peruse 
its potential as an inhibitor of the protein kinases TAK1, SGK1 and PKBβ. In 
addition, to further explore the potential of ianthelline as an agent selectively 
inhibiting PKBβ without affecting the closely related kinase PKBα. First and 
foremost though, the potential of ianthelline as an antifouling agent should be 
investigated. This could include further bioactivity and toxicity testing, as well as 
the production of analogues.  
 
The breitfussins represent a novel chemical scaffold that may provide inspiration 
for the design of future bioactive compounds. Before that can be realised, the 



















5. Concluding remarks 
 
The papers presented in this thesis are not collectively trying to answer one 
research problem, but are connected through a common research field: marine 
bioprospecting. The work conducted over the four years it took to complete this 
thesis has proven that the bioprospecting efforts put in at MabCent enables the 
discovery of both secondary metabolites with novel chemistry and bioactivity, as 
well as a previously reported compound which novel bioactivity. 
 
Natural sources have yielded many important new pharmaceuticals and utilisable 
products for a wide range of applications in the past.189,190 This can easily be 
explained, as evolution has favoured the tendency for organisms to produce 
chemically diverse compounds with structures optimised for specific target 
interactions. The previous success stories underscore the potential of secondary 
metabolites as a source of drugs and useful products, as well as emphasises the 
necessity of natural product research. Keeping in mind that the examination of 
only a small fraction of the biosphere for the potential content of bioactive 
secondary metabolites has resulted in 60% of all pharmaceuticals currently in use, 
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